Relaxin: reproductive safeguard turned cardiac?

Affiliations

Editorial

Stefan Janssens. Cardiovasc Res. 2017.

. 2017 May 1;113(6):553-555.

doi: 10.1093/cvr/cvx059.

¹ Department of Cardiovascular Sciences, KU Leuven, Herestraat 49, Leuven B-3000, Belgium.

No abstract available

Comment on

Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism.
Valle Raleigh J, Mauro AG, Devarakonda T, Marchetti C, He J, Kim E, Filippone S, Das A, Toldo S, Abbate A, Salloum FN. Valle Raleigh J, et al. Cardiovasc Res. 2017 May 1;113(6):609-619. doi: 10.1093/cvr/cvw246. Cardiovasc Res. 2017. PMID: 28073832
Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy.
Nonhoff J, Ricke-Hoch M, Mueller M, Stapel B, Pfeffer T, Kasten M, Scherr M, von Kaisenberg C, Bauersachs J, Haghikia A, Hilfiker-Kleiner D. Nonhoff J, et al. Cardiovasc Res. 2017 May 1;113(6):598-608. doi: 10.1093/cvr/cvw245. Cardiovasc Res. 2017. PMID: 28453725 Free PMC article.